Biocon finally gets Bristol-Myers to partner on oral insulin

As per the agreement, Bristol-Myers Squibb will have the right to exercise an option to obtain exclusive worldwide license to Biocon's program

Biocon announced today that it has entered into an option agreement with Bristol-Myers Squibb Company for Biocon’s IN-105, a prandial oral insulin product candidate.

Under the terms of the agreement, Bristol-Myers Squibb will have the right to exercise an option to obtain an exclusive worldwide license to the program. Biocon will conduct clinical studies to further characterise IN-105’s clinical profile according to a pre-agreed development program up to the completion of Phase II.

If Bristol-Myers Squibb exercises its option to license IN-105 following the successful completion of the Phase II trial, Bristol-Myers Squibb will assume full responsibility for the development program, including all development and commercialisation activities outside India.

 

Biocon will receive a license fee in addition to potential regulatory and commercial milestone payments and royalties on commercial sales of IN-105 outside India. And, it will retain exclusive rights to IN-105 in India.  

Kiran Mazumdar-Shaw, MD and Chairman of Biocon, said, “This agreement is one huge step closer to realising the dream of bringing oral insulin to market. We are excited to extend the excellent relationship we already enjoy with Bristol-Myers Squibb, and look forward to working closely with them to make this a reality.”

Diabetes is a chronic disease that affects about 350 million people worldwide. Long-term complications of diabetes include cardiovascular complications, peripheral vascular disease (leading to and including amputation), kidney failure, and other chronic diseases.  It is estimated that the direct and indirect costs of diabetes to the overall healthcare system amount to over $650 billion worldwide.